AlloVir briefly plunged amid concerns over selling pressure related to a recent lock-up agreement expiration.
As inflation moderates, Investors are optimistic for the second quarter earnings season and that optimism is evident in some of the top stories from this week
Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth.
The clinical-stage biotech's shares fell after the company announced a stock sale.
September S&P 500 futures (ESU23) are down -0.19%, and September Nasdaq 100 E-Mini futures (NQU23) are down -0.29% this morning after three major U.S. benchmark indices ended the regular session lower...
The company's lead therapy fared well in preventing infections for kidney transplant patients.
AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today reported financial results from the first quarter ended March 31, 2023. The company shared progress across its...
AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, announced today that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the...
AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced the presentation of positive long-term, follow-up data from the Phase 2 study of posoleucel...
Alaunos Therapeutics (TCRT) is expected to provide an update on its pipeline candidates, Library TCR-T cell therapy and mbIL-15 TCR-T cell therapy, in its fourth-quarter earnings.